Oscar Health (NYSE:OSCR) Director Mario Schlosser Sells 880,000 Shares

Oscar Health, Inc. (NYSE:OSCR) Director Mario Schlosser sold 880,000 shares of the business’s stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $29.38, for a total transaction of $25,854,400.00. Following the completion of the transaction, the director owned 480,866 shares in the company, valued at approximately $14,127,843.08. The trade was a 64.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mario Schlosser also recently made the following trade(s):

• On Tuesday, June 23rd, Mario Schlosser sold 147,500 shares of Oscar Health stock. The stock was sold at an average price of $29.38, for a total transaction of $4,333,550.00.
• On Tuesday, June 2nd, Mario Schlosser sold 34,120 shares of Oscar Health stock. The stock was sold at an average price of $21.94, for a total transaction of $748,592.80.

Oscar Health Stock Performance

Oscar Health stock traded down $0.52 during trading on Thursday, hitting $28.64. The stock had a trading volume of 5,572,050 shares, compared to its average volume of 7,777,062. The stock’s 50 day moving average is $22.48 and its two-hundred day moving average is $17.19. Oscar Health, Inc. has a 1 year low of $10.69 and a 1 year high of $30.38. The stock has a market cap of $8.63 billion, a price-to-earnings ratio of -48.54, a price-to-earnings-growth ratio of 2.09 and a beta of 2.37. The company has a quick ratio of 1.11, a current ratio of 1.11 and a debt-to-equity ratio of 0.26.

Oscar Health (NYSE:OSCR) last released its earnings results on Wednesday, May 6th. The company reported $2.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.11 by $0.96. The business had revenue of $4.65 billion during the quarter, compared to the consensus estimate of $4.90 billion. Oscar Health had a negative return on equity of 3.26% and a negative net margin of 0.30%.The business’s revenue for the quarter was up 52.6% on a year-over-year basis. During the same period last year, the business posted $0.92 earnings per share. As a group, analysts predict that Oscar Health, Inc. will post 0.47 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in OSCR. Vanguard Group Inc. boosted its holdings in shares of Oscar Health by 2.7% in the 4th quarter. Vanguard Group Inc. now owns 20,701,250 shares of the company’s stock worth $297,477,000 after purchasing an additional 540,851 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its holdings in shares of Oscar Health by 11.0% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 9,217,816 shares of the company’s stock valued at $132,461,000 after buying an additional 910,320 shares in the last quarter. Morgan Stanley lifted its position in Oscar Health by 42.8% in the 4th quarter. Morgan Stanley now owns 6,814,046 shares of the company’s stock worth $97,918,000 after buying an additional 2,043,758 shares during the last quarter. Thrive Capital Management LLC lifted its position in Oscar Health by 33.4% in the 4th quarter. Thrive Capital Management LLC now owns 6,343,617 shares of the company’s stock worth $85,258,000 after buying an additional 1,588,395 shares during the last quarter. Finally, BIT Capital GmbH boosted its stake in Oscar Health by 545.0% in the fourth quarter. BIT Capital GmbH now owns 6,186,267 shares of the company’s stock worth $88,897,000 after buying an additional 5,227,152 shares in the last quarter. 75.70% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

OSCR has been the subject of several recent research reports. UBS Group lifted their price objective on Oscar Health from $15.00 to $20.00 and gave the stock a “neutral” rating in a report on Thursday, May 7th. Barclays raised shares of Oscar Health from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $30.00 to $35.00 in a report on Wednesday, June 10th. Zacks Research lowered shares of Oscar Health from a “strong-buy” rating to a “hold” rating in a research report on Friday, June 5th. Jefferies Financial Group upgraded shares of Oscar Health from an “underperform” rating to a “hold” rating and lifted their target price for the stock from $10.00 to $16.00 in a research note on Monday, April 20th. Finally, Wolfe Research started coverage on shares of Oscar Health in a research report on Tuesday, May 5th. They issued a “peer perform” rating on the stock. Three research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $20.78.

About Oscar Health

Oscar Health, trading on the New York Stock Exchange under the ticker OSCR, is a technology-driven health insurance company headquartered in New York, New York. Founded in 2012 by Mario Schlosser, Joshua Kushner and Kevin Nazemi, the company was built with the goal of simplifying healthcare coverage and enhancing member experience. Oscar leverages a proprietary digital platform to streamline plan enrollment, claims administration and member support, distinguishing itself in the individual, family and small group insurance markets.

The company’s primary products include on-exchange individual and family medical plans under the Affordable Care Act, off-exchange plans, as well as Medicare Advantage offerings.